Automated Breast Ultrasound Systems (ABUS)

Automated Breast Ultrasound Systems (ABUS)

Global Automated Breast Ultrasound Systems (ABUS) Market to Reach US$2.0 Billion by 2030

The global market for Automated Breast Ultrasound Systems (ABUS) estimated at US$852.1 Million in the year 2023, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2023-2030. Automated Breast Volume Scanner, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Automated Breast Ultrasound System segment is estimated at 13.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$232.1 Million While China is Forecast to Grow at 17.8% CAGR

The Automated Breast Ultrasound Systems (ABUS) market in the U.S. is estimated at US$232.1 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$450.6 Million by the year 2030 trailing a CAGR of 17.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.1% and 11.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Automated Breast Ultrasound Systems (ABUS) Market - Key Trends and Drivers Summarized

Automated Breast Ultrasound Systems (ABUS) represent a significant advancement in imaging technology designed specifically for breast cancer screening. ABUS is used to obtain high-resolution ultrasound images of the breast, providing an effective supplementary tool alongside mammography, especially in women with dense breast tissue where mammography alone may not be as effective. This technology leverages high-frequency sound waves to produce detailed images of the breast tissue, aiding in the early detection of potentially cancerous lesions that may not be visible on mammograms. ABUS systems automate the imaging process, reducing operator dependency and variability, ensuring comprehensive coverage and consistency in imaging. This ability to consistently reproduce high-quality images makes ABUS a valuable tool in the early detection and ongoing monitoring of breast conditions, potentially leading to earlier diagnosis and treatment.

The design and functionality of ABUS have evolved to enhance user experience and patient comfort while maintaining high diagnostic accuracy. Modern ABUS machines are equipped with sophisticated software algorithms that analyze the ultrasound data to help differentiate between benign and malignant lesions, reducing the rate of false positives and the need for invasive biopsies. The systems are designed to scan the entire breast using a standardized approach, which minimizes the chance of missing areas of tissue that a manual ultrasound might overlook. Furthermore, ongoing advancements in ABUS technology focus on integrating artificial intelligence (AI) to improve image analysis capabilities. AI can assist radiologists by providing automated readings and highlighting areas of concern, which streamlines the workflow in busy clinical settings and may lead to more accurate assessments.

The growth in the Automated Breast Ultrasound Systems market is driven by several factors, including the rising global incidence of breast cancer, technological advancements in ultrasound imaging, and increasing awareness of the limitations of mammography in certain patient groups. As awareness of breast cancer screening increases, more women are seeking comprehensive screening solutions, particularly those who are identified as having dense breast tissue. Technological improvements in ABUS devices, such as enhanced imaging capabilities and the integration of AI, make these systems more appealing to healthcare providers by offering faster, more accurate readings and improving patient throughput. In addition, there is a growing demand for non-radiation-based diagnostic alternatives, which positions ABUS as a favorable option compared to traditional mammography, especially for younger women or those at higher risk of breast cancer. Regulatory bodies and healthcare organizations are also increasingly recommending supplementary ultrasound screening for women with dense breasts, further driving adoption of ABUS in clinical practices worldwide. These trends highlight the dynamic expansion of the ABUS market, fueled by both technological innovations and changing healthcare practices.

Select Competitors (Total 86 Featured) -

• Canon Medical Systems Corporation
• Delphinus Medical Technologies, Inc.
• Esaote SPA
• GE HealthCare
• Hologic, Inc
• Mindray DS USA, Inc.
• Planmed Oy
• QView Medical
• Samsung Healthcare
• Siemens Healthineers NV/SA
• SonoCiné, Inc.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.